Affiliation:
1. Ajinomoto Co., Inc. 1-1 Suzuki-cho Kawasaki Kanagawa 210-8681 Japan
2. Ajinomoto Bio-Pharma Services 11040 Roselle Street San Diego CA-92121 United States
Abstract
AbstractThis review outlines the latest findings on bioconjugation using lipoic acid ligase A (LplA), a key enzyme that allows the introduction of new functional groups into biomolecules. LplA functions via a characteristic mechanism of covalently binding orthologous lipoic acid derivatives in vivo to a specific 13 amino acid sequence called the LplA acceptor peptide (LAP). This unique functionality has enabled a wide range of applications, including cell‐surface modification, protein immobilization, fluorescent labeling of antibodies. Recently, the modification of proteins without LAP sequences has been demonstrated, suggesting their potential for future biopharmaceutical production. Although several review articles on enzyme ligation have been published, research on LplA remains limited. This review attempts to fill this gap by introducing LplA based on its mechanism, applications, and recent research reports.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献